LINE
NASDAQ
$43.22
Lineage Inc (LINE)
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.
Sector:
Real Estate
Industry:
Reit - Industrial
Hold
Target: $43.68 (+1.06%)
Market Cap
$9.99B
Free Cash Flow Yield
1.53%
Dividend Yield
4.78%
Beta (5Y)
0.85
Price Chart
Valuation
Market Cap$9.99B
Forward P/E769.23
P/S2.06
P/B1.24
Profitability
Total Revenue (TTM)$5.36B
Gross Profit (TTM)$1.72B
EBITDA$1.08B
Profit Margin-3.5%
Operating Margin2.8%
EPS-$0.64
Financial Health
Debt-to-Equity77.4%
Free Cash Flow Yield1.53%
Dividend Yield4.78%
Growth & Risk
Beta (5Y)0.85
Sharpe Ratio0.35